1	Sitagliptin decreases visceral fat and blood glucoses in women with polycystic ovarian
2	syndrome
3	Jessica K. Devin MD MSCI ¹ , Hui Nian PhD ² , Jorge E. Celedonio MD ³ , Patricia Wright RN ³ ,
4	Nancy J. Brown MD ³
5	¹ Division of Diabetes, Endocrinology, and Metabolism, ² Department of Biostatistics, ³ Division of
6	Clinical Pharmacology, Vanderbilt University Medical Center, Nashville, TN
7	Short Title: Sitagliptin improves VAT and blood glucoses in PCOS
8	Key words: dipeptidyl peptidase-4, growth hormone, insulin like growth factor-1, polycystic
9	ovarian syndrome, visceral adiposity
10	Corresponding Author: Jessica Devin, MD MSCI, Phone 615-498-8290,
11	Jessica.devin@vumc.org
12	Reprint Requests: Nancy J. Brown, MD, Phone 615-343-8701, Nancy.j.brown@vumc.org
13	Sources of Funding: This research was supported by Vanderbilt Clinical and Translational
14	Science Awards (CTSA) grant UL1 TR000445-06 from the NIH National Center for Advancing
15	Translational Sciences. The Vanderbilt Hormone Assay and Analytical Services Core is
16	supported by NIH grants DK059637 and DK020593. JKD was supported by K23HL11962
17	NHLBI/NIH and NJB by R01HL125426 from NHLBI/NIH.
18	Disclosures: The authors have nothing to disclose.
19	Clinical Trial Registration: This study was registered at www.clinicaltrials.gov as
20	NCT02122380 prior to enrollment of the first participant.

21 **Context:** Women with polycystic ovarian syndrome (PCOS) have decreased growth hormone 22 (GH), which can increase visceral adiposity (VAT) and impair vascular function. GH releasing hormone, a dipeptidyl peptidase-4 (DPP4) substrate, stimulates GH secretion. 23 24 Objective: We tested the hypothesis that DPP4 inhibition increases GH and improves glucose 25 levels and vascular function in women with PCOS. 26 **Methods:** Eighteen women with PCOS participated in a double-blinded, cross-over study. They received sitagliptin 100 mg vs. placebo daily for one month separated by an eight-week 27 28 washout. During each treatment, women underwent a 75-gram oral glucose tolerance test (OGTT), assessment of vascular function and body composition. Overnight GH secretion was 29 30 assessed via venous sampling every 10 minutes for 12 hours and analyzed using an automated deconvolution algorithm. 31 32 **Results**: During OGTT, sitagliptin increased GLP-1 (p<0.001), early insulin secretion (from mean insulinogenic index 1.9±1.2 (SD) to 3.2±3.1; p=0.02) and decreased peak glucose (mean 33 34 -17.2 mg/dL [95% CI -27.7, -6.6]; p<0.01). At one month, sitagliptin decreased VAT (from

1141.9 \pm 700.7 to 1055.1 \pm 710.1 g; p=0.02) but did not affect vascular function. Sitagliptin increased GH half-life (from 13.9 \pm 3.6 to 17.0 \pm 6.8 min, N=16; p=0.04) and interpulse interval (from 53.2 \pm 20.0 to 77.3 \pm 38.2 min, N=16; p<0.05) but did not increase mean overnight GH (p=0.92 vs. placebo).

39 **Conclusions:** Sitagliptin decreased the maximal glucose response to OGTT and VAT.

40 Sitagliptin did not increase overnight GH but increased GH half-life and the interpulse interval.

41

42 Precis: Sitagliptin improved body composition and blood glucoses following oral glucose load in
 43 women with PCOS. Sitagliptin potentiated GH half-life but did not increase overnight GH levels.

44 Introduction

Growth hormone (GH) is secreted in a pulsatile fashion from the pituitary gland and exerts its 45 effects either directly, via activation of the GH receptor, or indirectly, through hepatic insulin-like 46 47 growth factor-1 (IGF-1). In adults, GH has important effects on the vasculature and body composition. GH increases endothelium-dependent vasodilator function and reduces 48 49 inflammation.(1-3) We have previously shown that patients with low GH have impaired conduit artery vasodilator function along with decreased tissue-type plasminogen activator (tPA) activity 50 51 and a defective fibrinolytic response to venous occlusion.(4) Others have corroborated these 52 findings and further demonstrated that these vascular indices improve with GH replacement 53 therapy.(3,5) GH also has anabolic and lipolytic effects. Conversely, GH secretion is reduced 54 in obesity and particularly in individuals with visceral adiposity. Women with increased visceral 55 adipose tissue (VAT) demonstrate a four-fold reduction in mean GH levels as compared to 56 those without.(6) Normalization of GH secretion in patients with diminished GH affords one 57 potential mechanism to address simultaneously both VAT and cardiovascular risk. 58 Unfortunately, therapy with recombinant GH does not restore pulsatile secretion, is not subject 59 to physiologic negative feedback by IGF-1, and is limited by hyperglycemia.(7)

60

We propose that an alternative strategy to enhance endogenous GH secretion in humans is to inhibit the degradation of endogenous GH releasing hormone (GHRH) by the dipeptidyl peptidase-4 (DPP4) enzyme. GHRH is the primary stimulus for pituitary GH secretion and determines GH pulsatility. Endogenous GHRH has a half-life of six minutes as it is degraded and inactivated by DPP4.(8,9) Sitagliptin was the first oral DPP4 inhibitor approved by the US Food and Drug Administration for the management of hyperglycemia in patients with type 2 diabetes mellitus. Sitagliptin improves post-prandial hyperglycemia in a glucose-dependent

manner by decreasing the degradation of the incretin hormone, glucagon-like peptide-1 (GLP-1), and can therefore be safely given to patients without diabetes mellitus.(10) We recently found that acute DPP4 inhibition with sitagliptin enhances stimulated GH secretion and free IGF-1 levels in healthy, lean women. Moreover, while vasodilation and tPA activity levels increased in both men and women during stimulated GH secretion, women demonstrated an enhanced vascular response to increased GH.(11) The effect of chronic DPP4 inhibition on pulsatile GH secretion in individuals with low GH levels has not been studied.

75

76 Women with polycystic ovarian syndrome (PCOS) have decreased GH secretion characterized 77 by an impaired GH response to stimuli and a greater than 50% reduction in 24-hour mean GH 78 levels.(12-14) Approximately ten percent of reproductive-aged women in the United States are affected by PCOS at an estimated annual cost of over four billion dollars.(15) These women are 79 80 often overweight and are at increased risk for future cardiovascular disease and diabetes 81 mellitus. There are currently no approved medical therapies for women with PCOS; 82 management options include weight loss or medications aimed at controlling symptoms of hirsutism or oligomenorrhea, or treatment of insulin resistance.(16,17) In this study, we tested 83 84 the hypothesis that one month of DPP4 inhibition with sitagliptin would enhance overnight 85 pulsatile GH secretion in overweight women with PCOS and improve glucose metabolism. Given the effects of GH on the vasculature, we also hypothesized that an increase in GH would 86 enhance endothelial function and fibrinolysis. 87

88

89 Materials and Methods

90 Study Protocol

Eighteen women (BMI ≥25 kg/m²) with PCOS, 18 through 45 years of age completed a double-91 92 blind, randomized, placebo-controlled, crossover study. (See Table 1 for subject characteristics 93 and **Figure 1** for participant flow diagram.) The study adhered to the principles of the 94 Declaration of Helsinki and Title 45, U.S. Code of Federal Regulations, Part 46, Protection of 95 Human Subjects and was approved by the Vanderbilt University Medical Center Institutional 96 Review Board. All subjects provided written informed consent prior to initiation of study 97 procedures. A diagnosis of PCOS was confirmed when women met two out of the three 2003 98 Rotterdam criteria: oligomenorrhea (menstrual cycles occurring at intervals >35 days, or only 4-99 9 cycles per year) or secondary amenorrhea (no cycle in 3 months if previously regular or no 100 cycle in 9 months if previous oligomenorrheic); clinical and/or laboratory evidence of 101 hyperandrogenism; previous evidence of polycystic ovaries on ultrasound examination. Other 102 common causes of hyperandrogenemia and oligomenorrhea, including hyperprolactinemia, late-103 onset 21-hyroxylase deficiency, and inadequately treated hypothyroidism were excluded at the 104 time of screening visit.(18) Patients with a history of chronic illness, including diabetes mellitus, 105 hypertension, cardiovascular disease, and chronic renal or hepatic insufficiency as well as a 106 history of weight loss surgery or ongoing night-shift work were excluded. Women were required 107 to discontinue oral contraceptives for eight weeks and spironolactone for thirty days prior to 108 study enrollment, if applicable. One woman took a stable dose of metformin throughout the 109 study; other drugs known to alter glucose or insulin metabolism were not permitted. Pregnancy 110 was excluded in all women of child-bearing age by serum pregnancy testing prior to study drug 111 initiation and again prior to performing dual-energy x-ray absorptiometry (DEXA).

112

Women underwent two one-month treatment periods separated by wash-out period of at least
eight weeks (Figure 2). Subjects were assigned to treatment order (double-blinded sitagliptin
100 mg p.o. qd or matching placebo) using a block randomization algorithm. On each outpatient

116 and inpatient study day, subjects reported to the Vanderbilt Clinical Research Center (CRC) in 117 the morning after an overnight fast. After approximately two weeks of study drug, subjects 118 underwent an extended OGTT. One hour after oral study drug (sitagliptin vs. placebo) a 119 peripheral intravenous line was placed in the antecubital fossa of the non-dominant arm. Baseline venous samples and vital signs were obtained at least 60 minutes following study 120 121 drug. Oral glucola (75 grams) was then ingested within 10 minutes, and samples were obtained 122 over the following 270 minutes. Women were then discharged and continued daily study drug 123 at home for an additional two weeks.

124

125 On the last day of study drug, women again reported to the CRC following an overnight fast. 126 One hour after the last dose of oral study drug, vital signs, weight, and fasting venous samples were obtained via peripheral stick in the non-dominant arm. Women then underwent 127 128 assessment of endothelium-dependent and independent vasodilation in the dominant arm (see 129 "conduit artery vascular function" below). In the afternoon, total and regional body composition 130 was determined by a certified densitometrist using dual-energy X-ray absorptiometry (Lunar iDXA; GE Health Care, Madison, WI) with enCore software (version 13.6). Women also 131 completed the previously validated polycystic ovarian syndrome questionnaire (PCOSQ).(19-21) 132 133 In the evening, women underwent placement of an indwelling venous catheter and venous blood was sampled for GH every ten minutes from 8 PM until 8 AM. Meal content and 134 composition were standardized across all subjects, and intake of the standardized meals was 135 matched within each woman across study arms. Snacking and exercise were not permitted in 136 137 the CRC. Only water intake was permitted during GH sampling.

138

139 Conduit Artery Vascular Function

140 Endothelium-dependent vasodilation was evaluated in a temperature-controlled room in the 141 fasting state after 15 minutes of rest in the supine position. Participants were asked to refrain 142 from exercise, alcohol, caffeine, and anti-inflammatory medications for 24 hours preceding each 143 measurement. Studies could not be coordinated with the phase of the menstrual cycle due to 144 the infrequency or absence of cycles in the majority of our volunteers. Vascular images were 145 obtained by a single ultrasound-trained technician using an L12-3 broadband linear array 146 transducer attached to a high-resolution ultrasound machine (EPIQ7C; Phillips, Bothwell, WA). 147 A longitudinal image (parallel to the artery) was acquired just proximal to the antecubital fossa of the dominant arm with the transducer positioned to optimize images of the near and far wall 148 interfaces. Depth and gain settings were optimized to identify the interface between the lumen 149 150 and blood vessel wall. Anatomical landmarks were documented while positioning the probe, to 151 facilitate repositioning during repeated studies. A simultaneous electrocardiogram signal was 152 recorded throughout the imaging. To assess endothelium-dependent vasodilation, brachial 153 artery diameter was measured under basal conditions and during reactive hyperemia. Reactive 154 hyperemia was achieved by inflating a pneumatic cuff on the upper arm to 200 mmHg for five 155 minutes. The cuff was deflated and images of the artery were obtained continuously across the 156 cardiac cycle for 180 seconds after cuff release. Baseline velocity time integral (VTI) was 157 determined prior to cuff occlusion and hyperemic VTI was determined for ten beats post-cuff 158 release via pulse-wave spectral Doppler recordings. Following a 15-minute rest period, the 159 brachial artery was imaged again to re-establish basal conditions. Endothelium-independent 160 vasodilation was then determined by administering 0.4 mg nitroglycerin sublingually. The 161 brachial artery was imaged three minutes later for two minutes. Nitroglycerin was only administered if systolic blood pressure was at least 110 mm Hg, pulse at least 60 bpm, and with 162 163 the participant's consent (N=3 participants).

164

165 Acquisition and analysis of the DICOM-stored images was performed using software (Brachial 166 analyzer 5.0) designed for this purpose by Medical Imaging Applications LLC (lowa City, lowa). 167 The vessel wall-lumen interface was determined by derivative based edge detection following 168 identification of the region of interest by the blinded investigator (JKD). The selected region of 169 interest was consistent across study days for the same subject. The maximum diameter posthyperemia was obtained using previously described custom design software which 170 171 automatically calculates the time to peak and peak dilation.(22) This software implements the 172 method validated by Green et al. which uses a smoothing algorithm to correct for changes in the brachial artery diameter during the cardiac cycle.(23) The percent change in diameter, following 173 reactive hyperemia and nitroglycerin, was then calculated as percent vasodilation=[(peak 174 175 diameter-baseline diameter)/baseline diameter]*100. The reactive hyperemia-induced increase 176 in VTI relative to baseline was calculated as a ratio=hyperemia VTI/baseline VTI.

177

178 Laboratory Analyses

179 All samples were obtained after the first 3 mL of blood were discarded. Blood samples were collected on ice, centrifuged immediately and plasma stored at -80°C in pre-specified aliquots 180 until time of assay. All samples obtained from each subject during sitagliptin and placebo 181 182 treatment were simultaneously analyzed with internal controls. DPP4 activity was assayed by incubating 20 µl sample in 80 µl assay buffer (0.1 M Tris at a pH of 8.0; Bachem, Torrance, CA) 183 184 for 30 minutes at 37°C with colorimetric substrate [2 mM L-glycyl-L-prolyl p-nitroanilide 185 hydrochloride (Sigma Aldrich, St. Louis, MO)] for a total reaction volume of 200 µL, as previously described.(24) DPP4 antigen concentration was determined by enzyme-linked 186 187 immunoassay (ELISA) (eBioscience; San Diego, CA). The enzyme activity was assessed by measuring the increase in specific absorbance at 405 nm at 0, 15, and 30 minutes and was 188

189 expressed as nmol/mL/min. Percent DPP4 inhibition was determined by the equation: [1-(DPP4 activity during sitagliptin/DPP4 activity during placebo)]*100. GH levels were determined by 190 191 two-site immunoassay (Beckman Access Ultrasensitive human GH assay, Beckman Coulter, 192 Inc.) performed on the Dxl automated immunoassay system (Beckman Instruments; Chaska 193 MN) and calibrated against NIBSC WHO IS 98/574 with an analytic measurement range of 194 0.002 to 35 ng/mL. The first five subjects were analyzed at Brigham Research Assay Core 195 (Boston, MA); the intra-assay CV was 1.48-11.26% and the inter-assay CV was 1.96-14.4%. 196 The remaining subjects were analyzed at the Mayo Immunochemical Core Lab (Rochester, 197 MN); the intra-assay CV was 3.5% at 2.50 ng/mL and 3.2% at 14.8 ng/mL. The inter-assay CV's were 4.3% at 3.03 ng/mL, 5% at 7.23 ng/mL, and 4.8% at 13.62 ng/mL. All GH samples 198 from each subject were analyzed via batch in the same lab. Free IGF-1 was determined using a 199 200 commercially available ELISA (R & D systems; Minneapolis, MN) with a minimum detectable 201 range of 0.015 ng/mL, intra-assay CV 3.6-5% and inter-assay CV 10.0-11.1%. Total IGF-1 was 202 analyzed by Luminex® assay (Millipore Sigma; Burlington, MA), calibrated against the NIBSC WHO IS 02/254, with an intra-assay CV <10% and intra-assay CV<15%. IGF binding protein-1 203 204 (IGFBP-1) and IGFBP-3 were analyzed by commercially available ELISAs (RayBiotech: 205 Norcross GA) with a minimum detectable concentration of 5 pg/mL for IGF-BP1 and 80 pg/mL 206 for IGF-BP3. Both assays report an intra-assay CV <10% and inter-assay CV <12%. tPA 207 activity and plasminogen activator inhibitor-1 (PAI-1) antigen were measured in blood collected in acidified citrate anticoagulant (TriniLIZE[™] Stabilyte tubes, Tcoag; Bray Co. Wicklow, Ireland). 208 209 TPA activity was analyzed using an ELISA calibrated against NIBSC WHO IS 98/714 (Oxford 210 Biomedical Research, Oxford MS). PAI-1 antigen was analyzed using the TintElize PAI-1 211 antigen assay (Tcoag; Co. Wicklow, Ireland). Samples for analysis of active GLP-1, total 212 peptide YY (PYY) and PYY 3-36, and glucagon were collected in EDTA collection tubes 213 prepared with aprotinin and DPP4 inhibitor (Millipore Sigma; Burlington, MA). Active GLP-1 was analyzed in duplicate using the MILLEPLEX® MAP Human Metabolic Hormone Magnetic Bead 214

215 Panel (Millipore Sigma; Burlington, MA) with an intra-assay CV of <10% and inter-assay CV 216 <15%. Total PYY and PYY 3-36, glucagon, and insulin were analyzed in duplicate by 217 radioimmunoassay (Millipore Sigma; Burlington, MA) with intra-assay CVs of 3.7%, 2.3%, 1.6%, 218 and 3.3%, respectively. PYY 1-36 was calculated by subtracting PYY 3-36 from Total PYY. 219 Estradiol was also analyzed by radioimmunoassay (MP Biomedicals; Santa Ana, CA) with an 220 intra-assay CV of 3.9%. Blood glucoses were determined by Accu-Chek® Inform II bedside 221 glucometer (Roche Diagnostics; Indianapolis, IN); the same glucometer was used on each 222 outpatient study day. High-sensitivity C-reactive protein (hsCRP) was determined by commercially available ELISA (Hycult®Biotech; Plymouth Meeting, PA). Bioavailable 223 224 testosterone was calculated from testosterone measured via quantitative high-performance 225 liquid chromatography-tandem mass spectrometry (ARUP® Laboratories; Salt Lake City, Utah). 226 Sex hormone binding globulin was obtained via quantitative electrochemiluminescent 227 immunoassay (ARUP® Laboratories; Salt Lake City, Utah). F2-isoprostanes were determined 228 via gas chromatography/mass spectrometry assay, as previously described.(25) Total plasma 229 cholesterol and triglycerides were measured by standard enzymatic assays. HDL cholesterol 230 was measured via the enzymatic method after precipitation of VLDL and LDL using 231 polyethylene glycol reagent. From these data LDL cholesterol was calculated using the 232 Friedewald equation. Plasma free fatty acids were analyzed with a commercially available 233 enzymatic kit (Wako Life Sciences; Richmond, VA). The insulinogenic index, quantitative insulin sensitivity check index (QUICKI), homeostatic model assessment of insulin resistance (HOMA-234 235 IR) and Matsuda Index were calculated as previously described. (26,27)

236

237 Analysis of Growth Hormone Secretion

238 Overnight spontaneous GH secretion was assessed using an automated deconvolution 239 algorithm (AutoDecon Pulse_XP Software Package), which determines secretion events, adds 240 them to the current fit to test for statistical significance, and automatically removes any non-241 significant events until no additional statistically significant secretion events are found.(28) 242 AutoDecon has been validated for the analysis of endogenous pulsatile GH secretion from time-243 series data obtained via frequent venous sampling from an indwelling catheter every ten 244 minutes for twelve hours.(29,30) Initial algorithm estimates included the standard deviation of 245 the secretion events, set at one-half of the data-sampling interval (5 min), and a starting value 246 for the GH elimination half-life of 13 minutes based upon previously published data in adults with BMI >25 kg/m².(31) Initial values for basal secretion and concentration at t=0 were also 247 248 estimated from the secretion and concentration panels. AutoDecon then determined GH basal 249 secretion, half-life, median pulse mass and interpulse interval, number of GH peaks, and GH 250 area under the curve. Additional parameters of GH secretion including mean overnight GH 251 secretion, GH peak and nadir were determined via Microsoft Excel 2010. Missing data were 252 omitted from analyses.

253

254 Statistical Analysis

Data are presented in results tables as both mean ± standard deviation and median
[interquartile range, IQR], given that data is not normally distributed. We tested for carry-over
effect using the T-test approach proposed by Jones and Kenward.(32) Repeated measurement
continuous variable data from OGTT were summarized as mean over time (from baseline to 270
minutes) or area-under-the- curve (AUC) for the same time period. Unless otherwise noted, a
paired t-test was used to compare variables between treatment conditions with results
presented as the mean difference between treatments with 95% confidence interval (CI). Mixed

262 effect models were also used to analyze repeated measures data during the OGTT with a 263 random subject effect and with fixed effects of treatment (sitagliptin vs placebo), time and 264 treatment x time interaction. The baseline measurement was also included in each model. 265 Interaction terms were removed from the final model when the corresponding p value was >0.2. 266 Comparisons between treatments were made at each time-point using Wilcoxon signed rank 267 test. Spearman correlation was used to evaluate the association between continuous variables. 268 Analyses were performed using IBM SPSS software v. 23.0, GraphPad Prism 5 and R 2.15.0 269 (www.r-project.org). A p-value less than or equal to 0.05 was determined to be significant.

270

271 Sample Size Calculation

272 Sample size was calculated with Power and Sample Size Calculation (PS) Software using the 273 design for a paired t-test.(33) In a prior study mean baseline overnight GH was 0.7 ± SEM 0.2 μ g/L versus a mean overnight GH after therapy of 1.2 ± SEM 0.3 μ g/L (p<0.005) in 13 274 subjects.(31) With the enrollment of subjects in current study, we found that the standard 275 276 deviation (SD) of mean overnight GH was 0.51 µg/L (measurements from two periods combined), well below the SD of 0.72 μ g/L and 1.1 μ g/L observed in the prior study used in the 277 original sample size calculation. Conservatively assuming a SD of 0.6 µg/L in each group, we 278 279 calculated that a sample size of 16 women provides 93.2% power to detect a difference in GH 280 means of 0.5 µg/L.

281

282 **Results**

283 Effect of sitagliptin on DPP4 activity and glucose metabolism

284 Seventeen women completed the entire study. One woman completed two weeks of both 285 treatments and is also included in the analysis of the outpatient study days.(Figure 1) Sitagliptin

100 mg daily significantly decreased DPP4 activity (p<0.001 vs. placebo), as assessed on both the outpatient visit days (from 21.3 ± 8.0 to 8.8 ± 5.2 nmol/mL per minute) and the inpatient visit days (from 22.9 ± 6.0 to 9.9 ± 4.9 nmol/mL per minute).

289

290 Sitagliptin decreased blood glucose following ingestion of 75 grams of oral glucose, as 291 summarized as both average over time (mean difference -5.13 mg/dL, 95% CI [-10.26, 0.00]; 292 p=0.05), and AUC (mean difference -1476.25 mg/dL x 120 min, 95% CI [-2472.69, -479.81]; 293 p<0.01) (Figure 3A). Peak blood glucose following the oral glucose load was also lower during 294 sitagliptin treatment (mean difference -17.2 mg/dL, 95% CI [-27.7, -6.6]; p<0.01). The overall 295 effect of sitagliptin on metabolism of glucose varied with time (p<0.001). At 100 minutes, mean 296 blood glucose was 15.4 mg/dL (95% CI 8.7, 22.1; p<0.001) lower during sitagliptin treatment 297 than during placebo.

298

Sitagliptin also enhanced early insulin secretion, as demonstrated by an increase in the insulinogenic index (from 1.9 ± 1.2 to 3.2 ± 3.1 ; p=0.02) and insulin AUC for the first 30 minutes after glucose ingestion (mean difference 349.21 µU/mL x 30 min, 95% CI [39.3, 659.1]; p=0.05) (**Figure 3B**). Sitagliptin did not affect peripheral insulin resistance (Matsuda), hepatic insulin resistance (HOMA-IR) or insulin sensitivity (QUICKI), as determined on the day of the 75-gram OGTT (**Table 2**). Sitagliptin did not affect fasting blood glucose (p=0.572 vs. placebo) or fasting insulin levels (p=0.687 vs. placebo).

306

Sitagliptin increased fasting GLP-1 levels (p<0.001 vs. placebo) as well as GLP-1 levels during
 the 75-gram OGTT, summarized as average over time (mean difference 27.01 pg/mL, 95% CI

309	[18.01, 36.01]; p<0.001) (Figure 4A). Sitagliptin also increased peptide YY 1-36 (mean
310	difference 14.97 pg/mL, 95% CI [2.30, 27.63]; p=0.02) and decreased peptide YY 3-36 (mean
311	difference -39.78 pg/mL, 95% CI [-51.39, -28.17]; p<0.001). (Figure 4B and C) Sitagliptin did
312	not influence the change in free fatty acid levels or glucagon levels following oral glucose
313	ingestion (data not shown).
314	

315 Effect of sitagliptin on GH secretion and IGF-1 levels

Overnight GH secretion (GH AUC) correlated inversely with weight (placebo: r_s = -0.69, p=0.003;

sitagliptin: r_s =-0.71, p=0.002), VAT mass (placebo: r_s = -0.82, p<0.001; sitagliptin: r_s = -0.77,

p=0.001), high-sensitivity C-reactive protein (placebo: $r_s=-0.53$, p=0.035; sitagliptin: $r_s=-0.54$,

p=0.031), and HOMA-IR (placebo: r_s = -0.54, p=0.033; sitagliptin: r_s =-0.79, p=0.001), regardless

- 320 of drug treatment during the preceding month.
- 321

322 GH levels were appropriately suppressed following oral glucose ingestion and then increased 323 approximately 4 hours later. Sitagliptin did not significantly influence the late GH peak (mean 324 difference 0.31 ng/mL, 95% CI [-0.92, 1.54]; p=0.61) during the 75-gram OGTT. IGFBP-1 325 levels, summarized as average of time, were not affected by sitagliptin (mean difference -9.18 326 pg/mL, 95% CI [-104.73, 86.38]; p=0.84). Free IGF-1 levels also were unaffected by sitagliptin 327 (mean difference -0.01 ng/mL, 95% CI [-0.09, 0.07]; p=0.84). Free IGF-1 levels at each time point following oral glucose were: baseline 0.46 ± 0.22 ng/mL placebo vs. 0.44 ± 0.21 ng/mL 328 329 sitagliptin; 30 minutes after oral glucose 0.46 ± 0.19 ng/mL placebo vs. 0.43 ± 0.18 ng/mL 330 sitagliptin; 90 minutes after oral glucose 0.44 ± 0.20 ng/mL placebo vs. 0.46 ± 0.20 ng/mL sitagliptin; 150 minutes after oral glucose 0.49 ± 0.26 ng/mL placebo vs. 0.45 ± 0.22 ng/mL 331 332 sitagliptin.

333

334	During overnight sampling after one month of sitagliptin, GH half-life (p=0.04 vs. placebo) and
335	consequently the median interpulse interval (p<0.05 vs. placebo) both increased, but GH AUC
336	and mean GH were stable (Table 3). Representative plots of overnight sampling of GH from 3
337	subjects are included in Figure 5. One month of daily sitagliptin had no effect on fasting free
338	IGF-1 levels, total IGF-1 levels, or IGFBP-3 levels (Table 3).
339	
340	Effect of sitagliptin on vascular parameters and conduit artery vascular function
341	Sitagliptin increased heart rate during the 75-gram OGTT summarized as average over time
342	(mean difference 2 bpm, 95% CI [0.01, 4.06]; p<0.05) and during the inpatient study day (from
343	67.4 \pm 9.3 to 71.3 \pm 6.9 bpm; p<0.05). One month of sitagliptin did not affect inflammatory or
344	fibrinolytic markers. Sitagliptin also had no effect on conduit artery vascular function during
345	reactive hyperemia. (Table 4) A limited number of women (N=3) met criteria for assessment of
346	endothelium-independent vasodilation using nitroglycerin and agreed to its administration.
347	Sitagliptin did not influence vasodilation after 0.4 mg sublingual nitroglycerin (36.5% ± 13.7 after

348 placebo vs. $36.4\% \pm 9.0$ after sitagliptin, p>0.05).

349

350 Effect of sitagliptin on body composition and characteristics of PCOS

One month of sitagliptin therapy decreased VAT mass (p=0.02 vs. placebo) and volume (p=0.02 vs. placebo), but did not significantly affect weight or overall percent fat (**Table 5**). Sitagliptin decreased total cholesterol (from 168.8 ± 26.3 to 162.5 ± 22.2 mg/dL; p=0.02) largely due to a decrease in LDL (from 101.9 ± 23.8 to 96.2 ± 21.5 mg/dL; p=0.06). One-month treatment with sitagliptin did not influence estradiol or testosterone levels (**Table 5**). Sitagliptin did not affect

356	health-related quality of life domains (emotions, body hair, weight, infertility and menstrual
357	problems), as assessed by PCOS Questionnaire administered on the last day of each therapy
358	(p=1.00 vs. placebo for each domain).

359

360 Association between DPP4 inhibition and GH levels, VAT, and HOMA-IR

361 Sitagliptin did not increase overnight GH secretion or lower insulin resistance. Greater DPP4

inhibition in response to sitagliptin, however, correlated with GH levels, VAT and HOMA-IR.

- 363 The degree of DPP4 inhibition with sitagliptin correlated with GH secretion, such that DPP4
- inhibition was associated with overnight GH secretion (GH AUC: r_s = 0.60, p=0.02; mean GH: r_s =

0.59, p=0.02). DPP4 inhibition after sitagliptin was also associated with VAT mass (r_s = -0.66;

p<0.01), and HOMA-IR ($r_s=-0.64$; p=0.01). The correlations between DPP4 inhibition and GH

AUC, VAT, and HOMA-IR were no longer significant after controlling for BMI (GH AUC r_s=0.25,

p=0.38; VAT r_s =-0.31, p=0.25; HOMA-IR r_s =-0.15; p=0.61). Women with higher DPP4 inhibition

369 during sitagliptin treatment, i.e. those in whom the percent DPP4 inhibition (defined as [1-(DPP4

activity during sitagliptin/DPP4 activity during placebo)]*100) was above the median for the

women analyzed, had higher overnight GH secretion and lower VAT mass and HOMA-IR.

Figure 6 compares values between those with higher DPP4 inhibition and lower DPP4 inhibition

373 within the sitagliptin treatment. Similarly, women with greater DPP4 inhibition also had lower

374 BMI (30.3 \pm 3.4 vs. 38.5 \pm 6.3 kg/m²; p<0.01).

375

376 <u>Safety</u>

377 One woman was hospitalized with gallstone-induced pancreatitis after two doses of sitagliptin.

378 One woman reported intermittent abdominal pain while taking sitagliptin and another reported

dizziness. One woman taking sitagliptin reported dizziness towards the end of the OGTT,
another woman taking sitagliptin developed headache during the OGTT. There were no
reported instances of hypoglycemia while taking sitagliptin. Three woman reported nausea,
decreased appetite, and dizziness while taking placebo. One woman developed nausea during
the OGTT while taking placebo, and one experienced emesis. One woman developed shingles
while taking placebo. One woman developed headache, nausea, and dizziness following
nitroglycerin.

386

387 Discussion

388 This study tested the hypothesis that one-month treatment with the DPP4 inhibitor sitagliptin 389 would potentiate overnight GH secretion in overweight women with PCOS and improve glucose 390 levels. As expected, sitagliptin lowered blood glucose by increasing GLP-1 levels and 391 enhancing early insulin secretion following ingestion of oral glucose. Sitagliptin did not increase 392 mean overnight GH but did enhance GH half-life. Body composition also improved during 393 sitagliptin, as evidenced by a decrease in VAT, while weight and BMI remained stable. These findings indicate that DPP4 inhibition with sitagliptin decreases the maximal glucose response to 394 395 OGTT, improves body composition, and increases GH half-life in overweight women with 396 PCOS.

397

Altered GLP-1 and insulin secretion following oral glucose ingestion has previously been reported even in lean, glucose-tolerant women with PCOS. Women with PCOS have higher levels of c-peptide and tend to have higher levels of insulin secretion particularly in the first hour after glucose ingestion. While active GLP-1 levels are similar in women with PCOS and healthy volunteers early on, they are lower in women with PCOS after one hour.(34) The glucagon

response to hypoglycemia is also potentiated in obese women with PCOS as compared to
matched controls.(35) We hypothesized that sitagliptin, with its ability to potentiate postprandial GLP-1 secretion and suppress glucagon secretion, would mitigate these undesirable
post-glucose changes. We observed enhanced GLP-1 secretion during sitagliptin, but no
changes in glucagon levels.

408

409 Only one previous study has evaluated the effect of sitagliptin on glucose homeostasis in 410 women with PCOS. Ferjan et al. conducted a 12-week study of obese women with PCOS in 411 which women were randomized to open label sitagliptin 100 mg daily with lifestyle intervention 412 or lifestyle intervention alone following metformin withdrawal.(36) The investigators found that 413 sitagliptin improved beta cell function and even prevented the conversion from impaired glucose tolerance to type 2 diabetes mellitus in three of the women. The investigators did not appreciate 414 415 a significant decrease in glucose levels during OGTT. In contrast, we observed that sitagliptin 416 enhanced GLP-1 secretion following oral glucose ingestion which resulted in enhanced early 417 insulin secretion and a significant decrease in the blood glucose rise following oral glucose 418 ingestion. Our relatively more homogeneous study population and cross-over design likely 419 enabled us to detect better an improvement in blood glucose levels.

420

The effect of sitagliptin on post-prandial GH secretion has not previously been investigated. It is well known that oral glucose ingestion quickly inhibits GH secretion before a late stimulatory effect on GHRH-mediated GH levels. Relatively little is known, however, about the metabolic factors that influence GH secretion following oral glucose. Grottoli et al. demonstrated that early GH inhibition following glucose ingestion is lost in obesity but the late stimulatory effect is maintained.(37) Iranmanesh et al further demonstrated that nadir and peak rebound GH

427 secretion is influenced by VAT and SHBG in obese men.(38) Potential mechanisms by which 428 sitagliptin might alter the GH secretion in response to an OGTT in women with PCOS include 429 enhanced late GH secretion due to decreased degradation of the GHRH stimulus or mitigation 430 of the known inhibitory effects of hyperglycemia and free fatty acids on GH secretion. Although 431 sitagliptin lowered blood glucoses following oral glucose ingestion, we did not observe any 432 effect of sitagliptin on free fatty acids or on GH secretion. Skov et al also demonstrated that 433 intravenous GLP-1 infusion in men reduces IGFBP-1 and tended to increase IGF-1 434 bioactivity.(39) We did see an increase in GLP-1 and early insulin secretion, but this did not 435 significantly influence IGFBP-1 levels or free IGF-1 levels. Thus, it is unlikely that alterations in insulin secretion, blood glucoses, IGFBP-1, or GLP-1 levels contribute to the altered post-436 437 glucose GH secretion described in obesity. Furthermore, IGF-1 did not contribute to the 438 observed changes in glucose metabolism in our study participants.

439

440 Our study investigates a novel potential strategy to enhance endogenous GH secretion in a 441 population of patients demonstrated to have diminished GH levels. Obese individuals have diminished GH secretion, characterized by fewer GH pulses and shorter half-life duration.(40) 442 De Boer et. al. observed impaired overnight GH secretion in PCOS patients, irrespective of 443 444 weight and degree of insulin resistance.(12) We found that one month of sitagliptin therapy influences overnight GH secretion by increasing GH half-life. The inter-pulse interval, which 445 represents the time interval between secretion events and is partially dependent upon half-life in 446 addition to the previous inter-pulse interval and secretion event area, was also 447 448 increased.(28,29) Sitagliptin did not increase overnight GH levels. Although overnight GH 449 secretion correlated with DPP4 inhibition after sitagliptin. this was not the case after controlling 450 for BMI.

451

452 Our study was not designed to determine the mechanism by which sitagliptin influences the 453 overnight GH secretory profile. Possible mechanisms include decreased degradation of the 454 GHRH stimulus by DPP4, or increased GH as an indirect result of decreased VAT. In support 455 of the first mechanism, Makimura et. al. reported that twelve months of the DPP4-resistant GHRH analogue, tesamorelin, increases IGF-1 and selectively decreases VAT in obese 456 subjects with reduced GH secretion.(41) In contrast, we did not find that sitagliptin affected IGF-457 458 1 levels, yet VAT was still selectively affected. The lack of effect of sitagliptin on IGF-1 levels is 459 not surprising given that sitagliptin did not affect overnight GH secretion. In support of the second mechanism, Vahl et al found that abdominal obesity was the single most significant 460 461 determinant of pulsatile GH release, as determined by twenty-four hour GH profile.(42) Pijl et. 462 al. studied the effect of caloric restriction and 50% loss of body weight over a 3 to 5 month period in obese women and observed an increase in mean 24 hour GH secretion.(6) Similar to 463 464 our findings, they observed an increase in GH half-life with no effect on IGF-1 levels. This 465 report is consistent with our observation of a smaller yet significant decrease in VAT and 466 increase in GH half-life after only one month of sitagliptin in our subjects. Dichtel LE et al 467 reported that in overweight and obese women, increases in bioactive IGF-1, rather than total 468 IGF-1, drive GH-mediated body composition changes in the short-term. (43) A decrease in GH 469 binding protein may also have played a role in the observed changes in GH half-life and inter-470 pulse interval, as levels of GH binding protein directly correlate with VAT.(44) Lastly, another 471 mechanism possibly contributing to the decrease in VAT may be increased sympathetic activity. We have previously reported that sitagliptin increases sympathetic activity during concurrent 472 473 angiotensin converting-enzyme (ACE) inhibition by decreasing degradation of the DPP4 and 474 ACE substrate substance P.(45) We did observe an increase in heart rate following sitagliptin during the OGTT. 475

476

477	Others have reported that the addition of sitagliptin to metformin therapy improves body
478	composition in women with PCOS. Yan J et al reported that the addition of sitagliptin to
479	metformin treatment reduces VAT in patients with type 2 diabetes and non-alcoholic fatty liver
480	disease.(46) Ferjan et. al. similarly found that sitagliptin prevents weight regain, as compared to
481	metformin alone, in a 12-week prospective open label study in 24 obese women with PCOS
482	previously treated with liraglutide.(47) Thus, a growing body of evidence suggests that
483	sitagliptin selectively reduces VAT. Despite the improvements in VAT and GH secretion, we did
484	not observe an improvement in any of the clinical signs or symptoms experienced by women
485	with PCOS, as reported in a validated PCOS questionnaire. Longer duration of therapy would
486	likely be necessary to detect a change in these parameters. Similarly, androgen levels were not
487	affected by sitagliptin. We would expect androgen levels to improve in association with an
488	improvement in insulin resistance, and the latter was not observed.

489

490 Our study further evaluates cardiovascular endpoints, such as vascular function and fibrinolysis, which may be affected by enhanced GH secretion. GH directly improves vascular function 491 through several mechanisms, including activation of the GH receptor and downstream IGF-1 492 493 secretion (48), as well as GH receptor- and IGF-1-independent effects.(49) Li et. al. reported 494 that supra-physiologic circulating concentrations GH of approximately 33 ng/mL were necessary 495 to increase forearm blood flow.(1) Similarly, Napoli et al reported that intra-arterial GH infusion, 496 which raised local GH to approximately 40 ng/mL, increased forearm blood flow.(2) We 497 previously reported that sitagliptin increases forearm vasodilation, measured by strain gauge 498 plethysmography, in healthy women as assessed during stimulated GH secretion with peak 499 levels averaging 11.6 mg/dL.(11) In the present study, we did not observe any effect of

500 sitagliptin on conduit artery vascular function, however. Mean overnight GH levels in this study 501 in patients with PCOS were significantly lower than in our prior study in healthy women. The 502 changes in GH secretion induced by sitagliptin may have been insufficient to detect an effect on 503 forearm vasodilation. Other potential factors, such as increased sympathetic activity due to 504 decreased degradation of other DPP4 substrates such as substance P and neuropeptide Y, 505 may also have masked any GH-induced changes in vascular function. (45,50) It is also notable 506 that we did not observe any increase in vasodilation despite elevated GLP-1 levels during 507 sitagliptin. This is consistent with our previous observation that GLP-1 infusion into the forearm 508 vasculature does not increase vasodilation.(51)

509

510 We report for the first time the effect of chronic sitagliptin treatment on tPA activity and PAI-1 antigen levels. Despite the observed decrease in VAT and cholesterol, there was no significant 511 512 effect of sitagliptin on PAI-1. This contrasts with the data of Tani et al who found that eight-513 week treatment with vildagliptin decreased triglycerides and PAI-1 in poorly controlled type 2 514 diabetic patients.(52) The investigators suggested that improved lipid metabolism resulted in 515 down-regulation of PAI-1 production from the vascular endothelial cells. Triglyceride and PAI-1 516 levels in the women in the current study were one-third of the levels in their study population, 517 thus making it difficult to detect further down-regulation of PAI-1 production. We have previously demonstrated that GH affects tPA activity levels through the GH receptor and 518 519 downstream IGF-1 secretion,(11) but we did not observe any change in IGF-1 or tPA activity in 520 this study. We also did not see any effect of sitagliptin on inflammation, whereas Makdissi A et 521 al observed an anti-inflammatory effect of 100 mg daily sitagliptin on CRP, IL-6 and free fatty 522 acids after 12 weeks in patients with type 2 diabetes.(53) Differences in study populations or 523 treatment duration could account for these different observations.

524

Our study has limitations. PCOS is a heterogeneous disorder; women may be lean or 525 526 overweight and may or may not have insulin resistance. We studied a relatively homogenous 527 subset of women with PCOS and our results may not be generalizable to all women with PCOS. We chose to limit our study population to those women with a BMI of at least 25 kg/m² and to 528 exclude participants who were dieting with weight loss or titrating metformin therapy. This 529 subset of women with PCOS tends to represent the subset who are prescribed metformin in 530 531 order to improve glucose metabolism. We were interested in how sitagliptin influenced glucose 532 metabolism in overweight women with PCOS and we were limited to use of a manual glucometer for glucose measurements, though the same glucometer was used for each woman 533 534 across study days. We also did not include baseline endogenous GH secretory capacity as a 535 selection criterion for the women studied, as is done in many clinical trials evaluating the effect 536 of an intervention on GH secretion. If we had pre-selected for a relatively GH-deficient 537 population, we may have seen a more prominent effect of sitagliptin on overnight GH secretion. 538 We were unable to standardize timing of the endpoint measurements to womens' menstrual 539 cycles, as most women had infrequent menstrual cycles. This is particularly relevant in our 540 assessments of overnight GH secretion and vascular function. We did not observe a difference 541 in estradiol levels across study treatments, however. Our treatment duration was one month, 542 which may not have been sufficient to appreciate any effect of sitagliptin on clinical symptoms, or inflammatory or fibrinolytic markers. We chose to use the current FDA-approved daily dose 543 544 of sitagliptin, however we have previously demonstrated that 100 mg daily of sitagliptin is not as effective as single-dose 200 mg sitagliptin in inhibiting DPP4 activity in healthy individuals, and 545 546 that sitagliptin 100 mg daily is less effective in inhibiting DPP4 activity in individuals with type 2 547 diabetes mellitus and hypertension than in healthy individuals.(54) A higher dose of sitagliptin resulting in maximal DPP4 inhibition may have yielded a greater treatment effect on mean GH 548

and eliminated any effect of weight on response to sitagliptin. Our limited sample size may
have limited our conclusions on overnight GH secretion parameters. We observed low intraindividual variability in the pattern of overnight GH secretion, however, and the cross-over
design of the study would have increased our ability to detect treatment effects. Lastly, our
study design did not enable us to determine the mechanism by which sitagliptin may enhance
GH half-life.

555

In this study, we evaluated the previously unexplored effects of sitagliptin in overweight women 556 557 with PCOS. We demonstrate for the first time that sitagliptin enhances GLP-1 levels and early 558 insulin secretion and thereby decreases peak blood glucose following oral glucose ingestion in 559 these women. Second, we demonstrate that sitagliptin improves body composition, through an 560 undefined mechanism. As weight loss remains the cornerstone of treatment for PCOS, this is 561 also a highly desirable effect. Lastly, this study is the first to suggest an off-target effect of 562 sitagliptin on GH secretion in women with PCOS, potentiating GH half-life and the inter-pulse 563 interval. This is relevant as endogenous GH secretion is diminished in women with PCOS. (12-564 14) These data are the first to support the use of oral DPP4 inhibitor therapy to address elevated blood glucoses and body composition in women with PCOS, and to probe the 565 566 contribution of an altered somatotropic axis in the pathophysiology of this common disorder.

567 Acknowledgements:

- 568 We thank Anthony Dematteo, Zuofei Wang, and Aaron Falck for their technical assistance. We
- thank Drs. Kevin Niswender, Italo Biaggioni, and Melissa Wellons for their expertise and service
- 570 on the Data and Safety Monitoring Committee.
- 571

572		Poforoncos
575	1	Li G Del Rincon IP Jahn I A Wu Y Gavlinn B Thorner MO Liu Z Growth hormone
575	1.	everts acute vascular effects independent of systemic or muscle insulin-like growth
576		factor I. The Journal of clinical endocrinology and metabolism 2008; 93:1370-1385
577	2	Nanoli R. Guardasola V. Angelini V. D'Amico F. Zarra F. Matarazzo M. Sacca I. Acute
570	۷.	offocts of growth hormono on vascular function in human subjects. The Journal of
570		clinical endocrinology and metabolism 2003: 88:2817-2820
580	3	Sesmilo G. Biller BM. Llevadot I. Havden D. Hanson G. Rifai N. Klibanski A. Effects of
500	5.	arowth hormone administration on inflammatory and other cardiovascular risk markers in
582		men with growth bormone deficiency. A randomized controlled clinical trial Ann Intern
582		Med 2000: 133:111-122
584	4	Devin JK Blevins I.S. Jr. Verity DK Chen O. Bloodworth JR. Jr. Covington J. Vaughan
585	ч.	DE Markedly impaired fibrinolytic balance contributes to cardiovascular risk in adults
586		with growth hormone deficiency. The Journal of clinical endocrinology and metabolism
587		
588	5	Miliic D. Miliic P. Doknic M. Pekic S. Stojanovic M. Cvijovic G. Micic D. Popovic V.
589	0.	Growth hormone replacement normalizes impaired fibrinolysis: new insights into
590		endothelial dysfunction in patients with hypopituitarism and growth hormone deficiency
591		Growth Horm IGE Res 23:243-248
592	6.	Piil H. Langendonk JG. Burggraaf J. Frolich M. Cohen AF. Veldhuis JD. Meinders AF.
593	•	Altered neuroregulation of GH secretion in viscerally obese premenopausal women. The
594		Journal of clinical endocrinology and metabolism 2001: 86:5509-5515
595	7.	Jorgensen JO. Moller L. Krag M. Billestrup N. Christiansen JS. Effects of growth
596		hormone on glucose and fat metabolism in human subjects. Endocrinol Metab Clin North
597		Am 2007: 36:75-87
598	8.	Frohman LA, Downs TR, Heimer EP, Felix AM. Dipeptidylpeptidase IV and trypsin-like
599		enzymatic degradation of human growth hormone-releasing hormone in plasma. J Clin
600		Invest 1989; 83:1533-1540
601	9.	Frohman LA, Downs TR, Williams TC, Heimer EP, Pan YC, Felix AM. Rapid enzymatic
602		degradation of growth hormone-releasing hormone by plasma in vitro and in vivo to a
603		biologically inactive product cleaved at the NH2 terminus. J Clin Invest 1986; 78:906-913
604	10.	Bergman AJ, Stevens C, Zhou Y, Yi B, Laethem M, De Smet M, Snyder K, Hilliard D,
605		Tanaka W, Zeng W, Tanen M, Wang AQ, Chen L, Winchell G, Davies MJ, Ramael S,
606		Wagner JA, Herman GA. Pharmacokinetic and pharmacodynamic properties of multiple
607		oral doses of sitagliptin, a dipeptidyl peptidase-IV inhibitor: a double-blind, randomized,
608		placebo-controlled study in healthy male volunteers. Clin Ther 2006; 28:55-72
609	11.	Wilson JR, Brown NJ, Nian H, Yu C, Bidlingmaier M, Devin JK. Dipeptidyl Peptidase-4
610		Inhibition Potentiates Stimulated Growth Hormone Secretion and Vasodilation in
611		Women. J Am Heart Assoc 7
612	12.	de Boer JA, Lambalk CB, Hendriks HH, van Aken C, van der Veen EA, Schoemaker J.
613		Growth hormone secretion is impaired but not related to insulin sensitivity in non-obese
614		patients with polycystic ovary syndrome. Hum Reprod 2004; 19:504-509
615	13.	Orio F, Jr., Palomba S, Colao A, Russo T, Dentico C, Tauchmanova L, Savastano S,
616		Nappi C, Sultan C, Zullo F, Lombardi G. GH release after GHRH plus arginine
617		administration in obese and overweight women with polycystic ovary syndrome. J
618		Endocrinol Invest 2003; 26:117-122
619	14.	Piaditis GP, Kounadi TG, Rangou DB, Trovas GP, Kaklas NA, Tzonou AJ, Chlouverakis
620		CS. Dystunction of the growth hormone/insulin-like growth factor-I axis in women with
621		polycystic ovarian syndrome. Clin Endocrinol (Oxf) 1995; 42:635-640

15. 622 Azziz R, Marin C, Hog L, Badamgarav E, Song P. Health care-related economic burden 623 of the polycystic ovary syndrome during the reproductive life span. The Journal of clinical 624 endocrinology and metabolism 2005; 90:4650-4658 625 16. Use of insulin sensitizing agents in the treatment of polycystic ovary syndrome. Fertil Steril 2004: 82 Suppl 1:S181-183 626 17. Sirmans SM, Pate KA. Epidemiology, diagnosis, and management of polycystic ovary 627 628 syndrome. Clin Epidemiol 2013; 6:1-13 629 18. Rotterdam EA-SPCWG. Revised 2003 consensus on diagnostic criteria and long-term 630 health risks related to polycystic ovary syndrome. Fertil Steril 2004; 81:19-25 19. Cronin L, Guyatt G, Griffith L, Wong E, Azziz R, Futterweit W, Cook D, Dunaif A. 631 Development of a health-related quality-of-life questionnaire (PCOSQ) for women with 632 633 polycystic ovary syndrome (PCOS). The Journal of clinical endocrinology and 634 metabolism 1998; 83:1976-1987 20. Guvatt G. Weaver B. Cronin L. Doolev JA. Azziz R. Health-related quality of life in 635 636 women with polycystic ovary syndrome, a self-administered questionnaire, was validated. J Clin Epidemiol 2004; 57:1279-1287 637 21. Jones GL, Benes K, Clark TL, Denham R, Holder MG, Haynes TJ, Mulgrew NC, 638 639 Shepherd KE, Wilkinson VH, Singh M, Balen A, Lashen H, Ledger WL. The Polycystic 640 Ovary Syndrome Health-Related Quality of Life Questionnaire (PCOSQ): a validation. 641 Hum Reprod 2004; 19:371-377 Marinos A, Celedonio JE, Ramirez CE, Gottlieb J, Gamboa A, Hui N, Yu C, Stein CM, 642 22. Biaggioni I, Shibao CA. Time-Course Analysis of Flow Mediated Dilation for the 643 644 Evaluation of Endothelial Function After a High-Fat Meal in African Americans. J Am 645 Heart Assoc 4 646 23. Black MA, Cable NT, Thijssen DH, Green DJ. Importance of measuring the time course 647 of flow-mediated dilatation in humans. Hypertension 2008; 51:203-210 648 24. Lefebvre J, Murphey LJ, Hartert TV, Jiao Shan R, Simmons WH, Brown NJ. Dipeptidyl 649 peptidase IV activity in patients with ACE-inhibitor-associated angioedema. 650 Hypertension 2002; 39:460-464 Milne GL, Gao B, Terry ES, Zackert WE, Sanchez SC. Measurement of F2-651 25. 652 isoprostanes and isofurans using gas chromatography-mass spectrometry. Free Radic Biol Med 2013; 59:36-44 653 654 26. Singh B, Saxena A. Surrogate markers of insulin resistance: A review. World J Diabetes 655 2010; 1:36-47 Matsuda M, DeFronzo RA. Insulin sensitivity indices obtained from oral glucose 656 27. 657 tolerance testing: comparison with the euglycemic insulin clamp. Diabetes Care 1999; 658 22:1462-1470 659 28. Johnson ML, Pipes L, Veldhuis PP, Farhy LS, Boyd DG, Evans WS. AutoDecon, a 660 deconvolution algorithm for identification and characterization of luteinizing hormone secretory bursts: description and validation using synthetic data. Anal Biochem 2008; 661 662 381:8-17 Johnson ML, Pipes L, Veldhuis PP, Farhy LS, Nass R, Thorner MO, Evans WS. 663 29. AutoDecon: a robust numerical method for the quantification of pulsatile events. 664 665 Methods Enzymol 2009; 454:367-404 30. Veldhuis JD, Keenan DM. Model-based evaluation of growth hormone secretion. 666 Methods Enzymol 514:231-248 667 668 31. Stanley TL, Chen CY, Branch KL, Makimura H, Grinspoon SK. Effects of a growth 669 hormone-releasing hormone analog on endogenous GH pulsatility and insulin sensitivity in healthy men. The Journal of clinical endocrinology and metabolism 96:150-158 670 671 32. Jones B KM. Design and Analysis of Crossover Trials. Boca Raton, FL: CRC Press LLC.

672 33. Dupont WD, Plummer WD, Jr. Power and sample size calculations. A review and computer program. Control Clin Trials 1990; 11:116-128 673 674 34. Vrbikova J, Hill M, Bendlova B, Grimmichova T, Dvorakova K, Vondra K, Pacini G. 675 Incretin levels in polycystic ovary syndrome. European journal of endocrinology 2008: 159:121-127 676 35. Sam S, Vellanki P, Yalamanchi SK, Bergman RN, Dunaif A. Exaggerated glucagon 677 678 responses to hypoglycemia in women with polycystic ovary syndrome. Metabolism: clinical and experimental 71:125-131 679 Ferjan S, Janez A, Jensterle M. Dpp4 Inhibitor Sitagliptin as a Potential Treatment 680 36. Option in Metformin-Intolerant Obese Women with Polycystic Ovary Syndrome: A Pilot 681 Randomized Study. Endocr Pract 2018; 24:69-77 682 683 37. Grottoli S, Procopio M, Maccario M, Zini M, Oleandri SE, Tassone F, Valcavi R, Ghigo E. 684 In obesity, glucose load loses its early inhibitory, but maintains its late stimulatory, effect on somatotrope secretion. The Journal of clinical endocrinology and metabolism 1997; 685 686 82:2261-2265 38. Iranmanesh A, Lawson D, Veldhuis JD. Distinct metabolic surrogates predict basal and 687 688 rebound GH secretion after glucose ingestion in men. The Journal of clinical 689 endocrinology and metabolism 2012; 97:2172-2179 Skov J, Frystyk J, Christiansen JS. GLP-1 infusion reduces IGFBP-1 serum level in 39. 690 691 humans. Growth Horm IGF Res 2014; 24:67-70 692 40. Veldhuis JD, Iranmanesh A, Ho KK, Waters MJ, Johnson ML, Lizarralde G. Dual defects in pulsatile growth hormone secretion and clearance subserve the hyposomatotropism of 693 694 obesity in man. The Journal of clinical endocrinology and metabolism 1991; 72:51-59 41. 695 Makimura H, Feldpausch MN, Rope AM, Hemphill LC, Torriani M, Lee H, Grinspoon SK. 696 Metabolic effects of a growth hormone-releasing factor in obese subjects with reduced 697 growth hormone secretion: a randomized controlled trial. The Journal of clinical 698 endocrinology and metabolism 2012; 97:4769-4779 Vahl N, Jorgensen JO, Skjaerbaek C, Veldhuis JD, Orskov H, Christiansen JS. 699 42. 700 Abdominal adiposity rather than age and sex predicts mass and regularity of GH secretion in healthy adults. Am J Physiol 1997; 272:E1108-1116 701 702 43. Dichtel LE, Bjerre M, Schorr M, Bredella MA, Gerweck AV, Russell BM, Frystyk J, Miller 703 KK. The effect of growth hormone on bioactive IGF in overweight/obese women. Growth 704 Horm IGF Res 2018; 40:20-27 705 44. Fisker S, Vahl N, Jorgensen JO, Christiansen JS, Orskov H. Abdominal fat determines growth hormone-binding protein levels in healthy nonobese adults. The Journal of 706 707 clinical endocrinology and metabolism 1997; 82:123-128 708 45. Devin JK, Pretorius M, Nian H, Yu C, Billings FTt, Brown NJ. Substance P increases 709 sympathetic activity during combined angiotensin-converting enzyme and dipeptidyl 710 peptidase-4 inhibition. Hypertension 2014; 63:951-957 Yan J, Yao B, Kuang H, Yang X, Huang Q, Hong T, Li Y, Dou J, Yang W, Qin G, Yuan 711 46. H. Xiao X, Luo S, Shan Z, Deng H, Tan Y, Xu F, Xu W, Zeng L, Kang Z, Weng J. 712 713 Liraglutide, sitagliptin and insulin glargine added to metformin: the effect on body weight 714 and intrahepatic lipid in patients with type 2 diabetes mellitus and NAFLD. Hepatology 715 2018: 47. Ferjan S, Janez A, Jensterle M. Dipeptidyl Peptidase-4 Inhibitor Sitagliptin Prevented 716 Weight Regain in Obese Women with Polycystic Ovary Syndrome Previously Treated 717 718 with Liraglutide: A Pilot Randomized Study. Metabolic syndrome and related disorders 719 2017; 15:515-520 720 48. Thum T, Fleissner F, Klink I, Tsikas D, Jakob M, Bauersachs J, Stichtenoth DO. Growth 721 hormone treatment improves markers of systemic nitric oxide bioavailability via insulin-

722		like growth factor-I. The Journal of clinical endocrinology and metabolism 2007; 92:4172-
723		4179
724	49.	Tivesten A, Barlind A, Caidahl K, Klintland N, Cittadini A, Ohlsson C, Isgaard J. Growth
725		hormone-induced blood pressure decrease is associated with increased mRNA levels of
726		the vascular smooth muscle KATP channel. J Endocrinol 2004; 183:195-202
727	50.	Hubers SA, Wilson JR, Yu C, Nian H, Grouzmann E, Eugster P, Shibao CA, Billings FTt,
728		Jafarian Kerman S, Brown NJ. DPP (Dipeptidyl Peptidase)-4 Inhibition Potentiates the
729		Vasoconstrictor Response to NPY (Neuropeptide Y) in Humans During Renin-
730		Angiotensin-Aldosterone System Inhibition. Hypertension 72:712-719
731	51.	Devin JK, Pretorius M, Nian H, Yu C, Billings FTt, Brown NJ. Dipeptidyl-peptidase 4
732		inhibition and the vascular effects of glucagon-like peptide-1 and brain natriuretic peptide
733		in the human forearm. J Am Heart Assoc 2014; 3
734	52.	Tani S, Takahashi A, Nagao K, Hirayama A. Effect of dipeptidyl peptidase-4 inhibitor,
735		vildagliptin on plasminogen activator inhibitor-1 in patients with diabetes mellitus. Am J
736		Cardiol 2015; 115:454-460
737	53.	Makdissi A, Ghanim H, Vora M, Green K, Abuaysheh S, Chaudhuri A, Dhindsa S,
738		Dandona P. Sitagliptin exerts an antinflammatory action. The Journal of clinical
739		endocrinology and metabolism 2012; 97:3333-3341
740	54.	Wilson JR, Shuey MM, Brown NJ, Devin JK. Hypertension and Type 2 Diabetes Are
741		Associated With Decreased Inhibition of Dipeptidyl Peptidase-4 by Sitagliptin. J Endocr
742		Soc 2017; 1:1168-1178
7/3		
743		

745 Figure Legends

Figure 1. Participant Flow Diagram. Fifty-five women with polycystic ovarian syndrome (PCOS) were screened for study participation and 32 were determined to be eligible. Twentythree women agreed to participate and were randomized to study drug. Eighteen of these women participated in both study arms and their data were included in analyses. Complete data was available only from both outpatient visits in one woman. Another woman did not complete the overnight GH sampling portion of both inpatient visits.

752 Figure 2. Subjects participated in a double-blind, randomized, placebo-controlled,

753 **crossover study.** Eighteen women underwent two one-month treatment periods (sitagliptin

100 mg p.o. qd or matching placebo) separated by a washout period of at least eight weeks. On

each study day, subjects reported to the Vanderbilt Clinical Research Center (CRC) in the

morning after an overnight fast. After approximately two weeks of study drug, subjects

underwent an extended OGTT (75-grams oral glucola). Women were then discharged and

continued daily study drug at home for an additional two weeks. On the last day of study drug,

vomen (N=17) again reported to the CRC for collection of fasting venous samples,

760 measurement of endothelium-dependent and -independent vasodilation, measurement of total

and regional body composition via duel-energy x-ray absorptiometry, and frequent venous

sampling for GH every ten minutes for twelve hours overnight.

763 Figure 3. Sitagliptin improves blood glucoses (A) and early insulin secretion (B) following

764 **75 grams oral glucose.** Data were obtained on the outpatient visit day in 18 women and are

presented as mean \pm SD. The overall effect of sitagliptin on glucose levels varied with time

766 (p<0.001). P value was obtained via mixed effect model with a random subject effect and with

fixed effects of treatment (sitagliptin vs placebo), time and treatment x time interaction. * $p \le 0.05$

vs. placebo at corresponding timepoint, as obtained by Wilcoxon signed rank.

769 Figure 4. Sitagliptin increases both GLP-1 (A) and PYY 1-36 (B) and decreases PYY 3-36

(C) levels following oral 75 grams glucose. Data were obtained on the outpatient visit day in

18 women, and are expressed as mean \pm SD. Model based p values for treatment effect are:

p<0.001 for effect of sitagliptin on GLP-1, p<0.001 for effect of sitagliptin on PYY 1-36, p<0.001

for effect of sitagliptin on PYY 3-36. P value was obtained via mixed effect model with a random

subject effect and with fixed effects of treatment (sitagliptin vs placebo), time and treatment x

time interaction. *p \leq 0.05 vs. placebo at corresponding timepoint, as obtained by Wilcoxon

776 signed rank.

777 Figure 5. Representative plots of overnight GH levels from 3 subjects during placebo and

sitagliptin treatment. GH samples are obtained every 10 minutes from 8 PM to 8 AM. The
plots illustrate the high inter-individual variability but low intra-individual variability in overnight
GH secretion.

781 Figure 6. Women with a higher percent DPP4 inhibition had higher overnight GH

782 secretion (A and B, N=16) and lower VAT mass (C, N=17) and HOMA-IR (D, N=17) after

783 **one-month treatment with sitagliptin.** Data were obtained on the inpatient visit day and are

expressed as mean \pm SD. P values were calculated using the Wilcoxon rank sum test. Higher

percent DPP4 inhibition is defined as percent DPP4 inhibition at or greater than the median for

the 17 women included in the analysis, where percent DPP4 inhibition = [1-(DPP4 activity

787 during sitagliptin/DPP4 activity during placebo)]*100. Comparisons between higher and lower

788 DPP4 inhibition were not significant after controlling for BMI (GH AUC p=0.27; mean GH

789 p=0.24; VAT p=0.67; HOMA-IR p=0.66)

791	Table 1.	Subject	Characteristics
-----	----------	---------	-----------------

Variable	N=18
Age (years)	30.5 [7], 30.3 ± 3.3
Race	
White	13 (72%)
Black	3 (17%)
Asian	2 (11%)
Weight (kg)	81.0 [30.5], 90.6 ± 22.0
Body Mass Index (kg/m²)	32.9 [10.9], 34.1 ± 6.4
Overweight (25.0-29.9)	5 (28%)
Class I (30.0-34.9)	6 (33%)
Class II (35.0-39.9)	3 (17%)
Class III (≥ 40)	4 (22%)
Waist Circumference (cm)	101.7 [16.7], 104.8 ± 13.6
Waist-Hip Ratio	0.9 [0.1], 0.9 ± 0.1
Systolic Blood Pressure (mm Hg)	123.0 [20.0], 120.7 ± 12.0
Diastolic Blood Pressure (mmHg)	78.5 [13.0], 77.3 ± 7.9
Heart rate (beats per minute)	77.0 [12.8], 77.2 ± 9.9
PCOS Diagnostic Criteria	
Oligomenorrhea	17 (94%)
Hyperandrogenemia (hirsutism)	16 (89%)
Polycystic Ovaries on Ultrasound	11 (61%)
Current Metformin Use	1 (6%)
Fasting Blood Glucose (mg/dL)	83.5 [12.8], 85.5 ± 9.2
Bioavailable testosterone LC-MS (ng/dl)*	20.2 [15.3], 18.6 ± 10.0
Corrected bioavailable testosterone*†	0.8 [0.8], 0.8 ± 0.5
Sex hormone binding globulin (nmol/L) (normal range 30-135)	30.5 [60.3], 59.9 ± 65.6

792 Data shown as median [interquartile range] and mean ± SD. *N=17. † Corrected bioavailable

testosterone=bioavailable testosterone/assay upper limit of normal for age group. 6/17 (35%)

had bioavailable testosterone levels above the upper limit of normal.

795 Table 2. Effect of sitagliptin on glucose metabolism

Outpatient Day (N=18)	Placebo	Sitagliptin	P-Value
Blood glucose, 0-120 min AUC	15971.3 [3148.1]	13432.5 [3361.9]	0.009
	15353.8 ± 2708.6	13877.5 ± 2486.3	
Blood glucose, 0-30 min AUC	3176.3 [371.3]	3108.8 [451.9]	0.913
	3192.1 ± 356.9	3140.4 ± 421.3	
Insulin 0-120 min AUC	8642.9 [5670.4]	10031.1 [6878.2]	0.212
	11132.1 ± 8215.6	12169.3 ± 6568.3	
Insulin 0-30 min AUC	1337.0 [763.8]	1663.1 [1130.6]	0.054
	1522.1 ± 792.3	1871.3 ±843.6	
Insulinogenic index	1.84 [1.52]	2.7 [3.4]	0.016
	1.89 ± 1.20	3.2 ± 3.1	
Matsuda index	3.31 [2.51]	2.96 [2.13]	0.248
	3.27 ± 1.54	3.17 ± 1.99	
QUICKI	0.32 [0.03]	0.32 [0.03]	0.327
	0.33 ± 0.03	0.32 ± 0.03	
HOMA-IR	3.4 [2.3]	3.1 [2.7]	0.306
	3.5 ± 1.8	4.0 ± 2.5	
Inpatient Day (N=17)	Placebo	Sitagliptin	P-Value
Fasting blood glucose (mg/dL)*	93.0 [7.0]	90.0 [9.0]	0.572
	92.9 ± 10.3	90.9 ± 5.7	
Fasting insulin (µU/mL)	13.9 [6.9]	14.8 [9.2]	0.687
	16.5 ± 10.9	17.6 ± 9.8	
HOMA-IR*	3.2 [1.4]	3.7 [2.6]	0.691
	3.9 ± 2.7	4.1 ± 2.1	
Fasting glucagon (pg/mL)	48.8 [20.6]	45.2 [19.6]	0.906
	48.2 ± 16.4	49.0 ± 21.4	
Fasting GLP-1 (pg/mL)	8.2 [11.7]	26.9 [16.4]	<0.00
	9.8 ± 8.2	27.6 [13.8]	

Data shown as median [interquartile range] and mean \pm SD. P values obtained via Wilcoxon signed rank test.* Data available in 15 women.

Variable (N=16)	Placebo	Sitagliptin	P-Value
GH AUC (ng/mL per 12 hr)	428.9 [543.5]	524.6 [466.0]	0.918
	604.5 ± 398.7	593.5 ± 371.6	
Basal GH secretion (ng/mL min)*	0.001 [0.002]	0.002 [0.002]	0.496
	0.002 ± 0.002	0.002 ± 0.001	
GH half-life (min)	13.9 [2.7]	14.5 [8.0]	0.044
	13.9 ± 3.6	17.0 ± 6.8	
Number GH secretion events	10.5 [4.0]	8.5 [6.5]	0.058
	11.0 ±2.6	9.1 ± 3.3	
Median secretion pulse mass	1.1 [1.2]	1.3 [1.8]	0.756
	2.2 ± 3.4	1.7 ±1.5	
Median secretion pulse height	0.04 [0.05]	0.07 [0.16]	0.301
	0.10 ± 0.14	0.34 ± 0.63	
Median secretion interpulse interval	51.1 [34.4]	61.8 [60.6]	0.049
	53.2 ± 20.0	77.3 ± 38.2	
Maximum GH (ng/mL)	4.1 [5.5]	4.0 [3.5]	0.918
	5.1 ± 3.5	5.1 ± 4.4	
Minimum GH (ng/mL)	0.03 [0.03]	0.04 [0.05]	0.567
	0.04 ± 0.02	0.04 ± 0.02	
Mean GH (ng/mL)	0.63 [0.73]	0.74 [0.73]	0.918
	0.85 ± 0.54	0.84 ± 0.51	
Total IGF-1 (ng/mL)†	81.4 [57.0]	86.6 [52.1]	0.586
	88.7 ± 28.6	88.8 ± 29.7	
Free IGF-1 (ng/mL)†	0.31 [0.27]	0.38 [0.18]	0.523
	0.40 ± 0.26	0.43 ± 0.25	
IGFBP-1 (pg/mL)	184.4 [149.4]	158.2 [469.6]	0.326
	263.6 ± 298.3	325.2 ± 365.3	
IGFBP-3 (ng/mL)†	17.1 [5.9]	18.9 [3.4]	0.687
	18.5 ± 4.3	18.6 ± 2.4	
IGF-1/IGFBP-3†	4.8 [3.2]	4.4 [3.2]	0.906
	5.1 ± 2.2	4.9 [1.9]	

796 Table 3. Effect of sitagliptin on overnight GH secretion and IGF-1 levels

Data shown as median [interquartile range] and mean \pm SD. P values obtained via Wilcoxon signed rank test.*Data available in 15 women. † Data available in 17 women. IGF-1 and IGFBP represent morning fasting levels. GH levels were obtained every 10 minutes from 8 PM until 8 AM.

Variable (N=17)	Placebo	Sitagliptin	P-Value
Systolic Blood Pressure (mm Hg)	114.7 [18.7]	115.0 [16.2]	0.518
	117.8 ± 11.6	115.6 ± 8.7	
Diastolic Blood Pressure (mmHg)	75.0 [8.9]	73.0 [11.0]	1.000
	73.8 ± 7.4	73.7 ± 7.8	
Heart rate (beats per minute)	67.0 [14.2]	68.0 [7.0]	0.046
	67.4 ± 9.3	71.3 ± 6.9	
Baseline artery diameter (mm)	3.14 [0.55]	3.12 [0.62]	0.796
	3.16 ± 0.43	3.13 ± 0.37	
Baseline flow integral (m)	0.12 [0.04]	0.17 [0.07]	0.266
	0.15 ± 0.08	0.18 ± 0.08	
Peak FMD (mm)	3.53 [0.66]	3.48 [0.54]	0.344
	3.58 ± 0.47	3.53 ± 0.36	
Time of peak FMD (sec)	59.00 [37.82]	64.66 [46.56]	0.356
	60.71 ± 30.80	75.55 ± 35.02	
Diameter increase (mm)	0.39 [0.26]	0.40 [0.23]	0.705
	0.43 ± 0.16	0.40 ± 0.16	
Flow-mediated vasodilation (%)	12.42 [8.28]	14.24 [8.45]	0.943
	13.63 ± 5.27	13.00 ± 5.34	
Peak VTI (m)*	1.13 [0.34]	1.14 [0.27]	0.717
	1.12 ± 0.23	1.13 ± 0.32	
VTI, fold increase*	8.37 [3.49]	7.26 [4.35]	0.234
	8.34 ± 2.66	7.38 ± 2.79	
tPA activity (IU/mL)	0.21 [0.40]	0.23 [0.82]	0.831
	0.40 ± 0.47	0.44 ± 0.46	
PAI-1 antigen (ng/mL)*	8.78 [7.33]	9.72 [4.77]	0.959
	10.96 ± 7.51	11.27 ± 8.05	
hsCRP (mg/L)	3.51 [4.40]	2.90 [3.45]	0.619
	4.43 ± 4.00	4.92 ± 5.36	
F2 Isoprostanes (pg/mL)*	55.74 [44.02]	50.02 [42.26]	0.836
	68.16 ± 45.69	62.01 ± 30.25	

799 Table 4. Effect of sitagliptin on vascular parameters and conduit artery vascular function

Bota shown as median [interquartile range] and mean \pm SD. P values obtained via Wilcoxon

signed rank test. *Data available in 16 women.

Variable (N=17)	Placebo	Sitagliptin	P-value
Weight (kg)	81.0 [28.0]	81.6 [27.1]	0.619
	90.4 ± 21.7	90.2 ± 22.1	
Body Mass Index (kg/m ²)	32.1 [10.7]	32.4 [10.4]	0.586
	34.3 ± 6.4	34.2 ± 6.4	
Waist Circumference (cm)	105.9 [27.7]	105.0 [18.7]	0.381
	105.5 ± 18.0	104.0 ± 15.4	
Waist-Hip Ratio*	0.89 [0.12]	0.87 [0.10]	0.326
	0.88 ± 0.07	0.87 ± 0.07	
Percent Body Fat (%)	46.2 [5.2]	45.8 [6.5]	0.058
	46.8 ± 5.4	46.3 ± 5.0	
Fat (kg)	36.4 [16.9]	35.5 [18.0]	0.093
	41.6 ± 14.3	40.9 ± 14.5	
Lean Body Mass (kg)	43.9 [10.1]	44.6 [10.4]	0.758
	45.6 ± 7.4	45.8 ± 7.9	
/AT Volume (cm ³)	1199.0 [744.0]	959.0 [820.5]	0.022
	1210.6 ± 743.0	1118.4 ± 752.5	
/AT Mass (g)	1131.0 [702.0]	904.0 [774.0]	0.022
	1141.9 ± 700.7	1055.1 ± 710.1	
Android (% fat)†	54.1 [9.2]	51.9 [11.2]	0.037
	54.0 ± 7.6	52.8 ± 7.0	
Bioavailable Testosterone (ng/dL)*	23.2 [11.5]	16.1 [12.0]	0.109
	22.9 ± 10.3	19.8 ± 10.5	
Total Testosterone (ng/dL)	43.0 [25.0]	36.0 [31.0]	0.266
	48.4 ± 24.3	45.1 ± 27.5	
SHBG (nmol/L)*	25.5 [20.0]	31.5 [18.8]	0.325
	33.4 ± 21.1	30.7 ±15.7	
Estradiol (pg/mL)	212.9 [140.6]	210.2 [91.9]	0.407
	233.5 ± 118.9	214.6 ± 71.4	
Total Cholesterol (mg/dL)	169.0 [52.5]	165.0 [32.0]	0.020
	168.8 ± 26.3	162.5 ± 22.2	

802 Table 5. Effect of sitagliptin on body composition and characteristics of PCOS

LDL (mg/dL)	93.0 [45.0]	93.0 [37.5]	0.055
	101.9 ± 23.8	96.2 ± 21.5	
HDL (mg/dL)	49.0 [18.5]	51.0 [15.0]	0.462
	53.8 ± 18.3	52.8 ±15.3	
Triglycerides (mg/dL)	65.0 [39.0]	53.0 [58.5]	0.887
	64.8 ± 24.0	67.6 ± 36.9	

⁸⁰³ Data shown as median [interquartile range] and mean ± SD. P values obtained via Wilcoxon

signed rank test. *Data available in 16 women. † Android (% fat) represents the %total fat within

the android (central) region, as opposed to the gynoid (hip and thigh) region.

Assessed for eligibility let study criteria but meeting study criteria (N+23) Advarse Event (1) · Non-compliance(1) study other is at Lette follow up (1) time of interim Acreen Arm 2: Crossed Over to other Study Intervention (N=2) inte Included in (N=18)









